Evidence map›Paper›PMID 40069181›Full record

ReviewNPJ biofilms and microbiomes2025

Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation.

Jiaao Sun, Shiyan Song, Jiahua Liu, Feng Chen, Xiaorui Li, Guangzhen Wu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NPJ biofilms and microbiomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Microbiome-guided cancer immunotherapy: immune mechanisms, resistance pathways, and translational opportunities for precision oncology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiaao Sun *Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Shiyan Song *Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Jiahua Liu *Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Feng ChenDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China. dmuchenfeng@163.com.
Xiaorui LiDepartment of oncology, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China. xiaorui_0513@163.com.
Guangzhen WuDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China. wuguang0613@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In order to decipher the relationship between gut microbiota imbalance and cancer, this paper reviewed the role of intestinal microbiota in anticancer therapy and related mechanisms, discussed the current research status of gut microbiota as a biomarker of cancer, and finally summarized the reasonable means of regulating gut microbiota to assist cancer therapy. Overall, our study reveals that the gut microbiota can serve as a potential target for improving cancer management.

Indexed as

Antineoplastic AgentsGastrointestinal MicrobiomeNeoplasmsAnimalsBacteriaDysbiosisHumansAntineoplastic Agents

Identifiers

PMID40069181
PMCPMC11897378

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.